Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Articaine vs Lidocaine for IANB Nerve Damage Risk
NCT06564987Phase 1Recruiting
- Sponsor
- Cleveland Dental Institute
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, triple-blind trial of articaine in pain (2 arms), sponsored by Cleveland Dental Institute. Primary endpoint: Risk of nerve damage assessed by Electromyograph at 3 months. Started Jan 2024; status: recruiting.
02
Drugs
articaine
03
Conditions
pain
Beyond the preview
Go deeper on NCT06564987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564987.